Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Core Viewpoint - Bright Minds Biosciences Inc. is hosting a virtual R&D Day on May 20, 2025, to discuss its research on treatments for drug-resistant epilepsy and other CNS disorders [1][2]. Group 1: Event Details - The virtual R&D Day will take place from 10:00 am to 11:30 am ET and will include presentations from Key Opinion Leaders in epilepsy research [2][3]. - The event will cover the unmet needs in absence seizures and provide an overview of the Company's BREAKTHROUGH study, which is a Phase 2 clinical trial evaluating BMB-101 for adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy [2]. Group 2: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline targeting conditions like epilepsy and depression [4]. - The Company has developed a unique platform of highly selective serotonergic agonists, which has led to a rich portfolio of new chemical entity programs within neurology and psychiatry [5].